SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

The primary catalyst for movement is the cancellation of Larry Ellison's plan to sell up to 50 million shares, which the community views as a bullish removal of a major supply overhang. Traders are heavily debating whether this news will trigger a short squeeze or if lingering concerns regarding the company's high capital expenditures and debt load will pressure the stock.

Hunter Biden’s Laptop (LAPTOP) is a memecoin referencing the eponymous Hunter Biden laptop sensation that’s been a fixture in global media news cycles for the past six years. LAPTOP is a fungible, freely transferable, non-yield-bearing ERC-20 token on Base. As a memecoin, LAPTOP has no utility, but incorporates two novel distribution mechanics designed to promote long-term community growth: a large community airdrop and an event-based supply mechanism.

Hunter Biden's Laptop

The community is discussing the rapid and significant collapse of the meme coin shortly after its launch, with many traders labeling the event a market rug pull. Investors express frustration over substantial financial losses, while the conversation remains heavily polarized by political sentiment and widespread skepticism toward the project.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech shares are experiencing downward pressure following a fourth-quarter earnings report that missed revenue and EPS expectations, coupled with the announcement that its co-founders plan to step down by the end of the year to start a new independent mRNA venture. Investors are reacting negatively to the leadership transition and weak 2026 revenue guidance, despite the company's strong cash position and ongoing clinical trials in its oncology pipeline.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending due to significant insider buying, including $50 million in open-market purchases by co-CEOs, as traders watch for upcoming clinical data and the November PDUFA date for its lead oncology asset, ivonescimab. While some participants view the insider activity and recent trial updates as a strong bullish setup, others remain focused on the company's capital needs and the risks associated with regulatory uncertainty.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending amid highly polarized sentiment, with some traders debating potential price floors and technical setups while vocal critics mock long-term holders as "suckers" for the asset's sustained multi-year downtrend. Discussion frequently centers on frustration over previous missed profit opportunities and skepticism regarding the project's long-term utility.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is trending following a JPMorgan downgrade that shifted its rating to Neutral from Overweight and lowered the price target due to concerns over macroeconomic headwinds and weak organic growth. While traders express frustration with the stock's price action and management, others highlight the company's market share gains, improved customer metrics, and ongoing share repurchases as reasons to remain bullish.

ServiceTitan, Inc. engages in the collection of field service activities required to install, maintain, and service the infrastructure and systems of residences and commercial buildings. The company was founded by Ara Mahdessian and Vahe Kuzoyan on June 8, 2008 and is headquartered in Glendale, CA.

ServiceTitan Inc. - Ordinary Shares - Class A

ServiceTitan 

ServiceTitan shares faced significant downward pressure and high volatility following the release of quarterly results, where a soft revenue outlook for the upcoming quarter overshadowed a top-line beat. Traders expressed frustration with the stock's recent performance, while some viewed the price drop as a buying opportunity given the company's long-term growth prospects.

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Opus Genetics Inc.

Opus Genetics (IRD) is trending as traders react to positive clinical data from the low-dose cohort of its OPGx-BEST1 trial, with many in the community anticipating a significant upward trend ahead of future catalysts. While bullish sentiment dominates due to the trial results and institutional price target upgrades, some participants express caution regarding potential dilution and the company's long-term capital strategy.

VeChain is a public Layer-1 blockchain designed for real-world applications. Founded in 2015, its VeChainThor network supports enterprise and consumer use cases involving supply chains, product provenance, sustainability, digital product passports, tokenized incentives and verifiable data.  VeChainThor combines EVM-compatible smart contracts with a dual-token model, native fee delegation and multi-clause transactions. VET is the network’s native asset and staking collateral, while VTHO is used to pay transaction fees and execute smart contracts.  VeChain’s ecosystem includes VeBetter, an app platform that rewards verified positive actions; StarGate, its NFT-based staking platform; VeWorld, its self-custody wallet; and VeWorld.ai, its AI-agent platform. In its April 2026 roadmap, VeChain reported that VeBetter had reached 5.3 million users, more than 50 live applications and over 50 million verified actions.  VeChain has also worked with organizations including Walmart China, DNV, PwC, Boston Consulting Group and UFC across enterprise, sustainability and consumer initiatives.

Vechain

Vechain is currently trending amid widespread community frustration regarding its long-term price performance and ongoing decline in market rank. Traders are debating whether the asset is a viable long-term investment or a failed project, with sentiment polarized between those continuing to accumulate at lower levels and others exiting their positions.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is experiencing significant stock volatility driven by heavy insider selling, concerns over lock-up period expirations, and investor reactions to the company's competitive position against major GPU providers. While some traders view the recent price decline as a buying opportunity based on the company's wafer-scale technology and infrastructure growth, others remain skeptical, citing valuation concerns and aggressive short-selling activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China

Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.

Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday

U.S. stocks rose Thursday; Summit Therapeutics jumped 10.1% after Phase III results, while Snowflake and other stocks rallied.read more...

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China

Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or...

Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer  

Rasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Summit gains as positive HARMONi-GI1 data show ivonescimab's OS benefit in biliary tract cancer, expanding its potential beyond NSCLC.

Summit’s Global Lung Cancer Trials Gain Credibility After Akeso’s Phase 3 Data, Says Guggenheim

Equity

Akeso reported positive late-stage data for Ivonescimab, a drug that Summit Therapeutics holds the rights to develop and sell outside China.

Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy

Summit Therapeutics partner Akeso Phase 3 HARMONi-GI1 trial shows ivonescimab outperforms durvalumab in overall survival for advanced biliary tract cancer.read more...

Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday

U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and more.read more...

Futures Flat Ahead Of Key PCE Report, Nvidia Earnings

Futures Flat Ahead Of Key PCE Report, Nvidia Earnings

 Stock futures are are flat and Treasuries slipped while oil stumbled heading into today's PCE report and NVDA earnings. As of 8:00am ET, S&P Futures are unchanged and Nasdaq futures drop 0.2% as?NVDA and MRVL both rise 0.2% with...

Bearish Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Current Price	$17.55
Prev Close	$17.00
Open	$17.20
Dividend Yield	0.00%
50-Day Moving Average	$14.46
Beta	1.60
Avg. Volume	5.42M
PE Ratio	-15.68

52-Week High	$29.23
52-Week Low	$12.07
Market Capitalization	$14B
EPS (Annual)	-$1.44
Price to Book	22.09
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SMMT Fundamentals